NCT03843775: A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRAF
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient tumor must harbor an activating BRAF mutation or a fusion involving the kinase domain of BRAF – see trial for details
Exclusions: Patients with leptomeningeal disease; Patients with symptomatic untreated brain metastasis – see trial for details; Patients with prior treatment with any RAF, MEK, or ERK inhibitors (such as vemurafenib, dabrafenib, encorafenib; trametinib, cobimetinib, binimetinib, selumetinib; or BVD-523, respectively)

Comments are closed.

Up ↑